Drug Profile


Alternative Names: PVAC

Latest Information Update: 29 Dec 2003

Price : $50

At a glance

  • Originator SR Pharma
  • Class Antipsoriatics; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriasis; Scleroderma

Most Recent Events

  • 29 Dec 2003 Discontinued - Phase-I for Scleroderma in USA (unspecified route)
  • 22 Dec 2003 Discontinued - Phase-II for Psoriasis in Brazil (Intradermal)
  • 22 Dec 2003 Discontinued - Phase-II for Psoriasis in New Zealand (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top